Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 1
2018 2
2019 2
2020 3
2021 2
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

13 results
Results by year
Filters applied: . Clear all
Page 1
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group. Hammitt LL, et al. Among authors: wahlby hamren u. N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275. N Engl J Med. 2022. PMID: 35235726 Clinical Trial.
A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.
Cheung SYA, Parkinson J, Wählby-Hamrén U, Dota CD, Kragh ÅM, Bergenholm L, Vik T, Collins T, Arfvidsson C, Pollard CE, Tomkinson HK, Hamrén B. Cheung SYA, et al. Among authors: wahlby hamren u. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):365-381. doi: 10.1007/s10928-018-9589-6. Epub 2018 May 7. J Pharmacokinet Pharmacodyn. 2018. PMID: 29736890 Clinical Trial.
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Balaguer V, Albayaty M, Jimenez E, Wählby-Hamrén U, Astbury C, Seoane B, Malice MP, Lei A, Aggarwal A, Psallidas I. Balaguer V, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):212. doi: 10.1186/s12931-020-01474-1. Respir Res. 2020. PMID: 32907575 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Jimenez E, Astbury C, Albayaty M, Wählby-Hamrén U, Seoane B, Villarroel C, Pujol H, Bermejo MJ, Aggarwal A, Psallidas I. Jimenez E, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):211. doi: 10.1186/s12931-020-01470-5. Respir Res. 2020. PMID: 32907576 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D, Balaguer V, Astbury C, Wählby-Hamrén U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Singh D, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7. Respir Res. 2020. PMID: 32907566 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers.
Prothon S, Wählby Hamrén U, Tehler U, Yoon E, Forsman H, Arfvidsson C, Aggarwal A, Chen Y. Prothon S, et al. Among authors: wahlby hamren u. Drug Des Devel Ther. 2019 Nov 12;13:3845-3853. doi: 10.2147/DDDT.S215170. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31814707 Free PMC article. Clinical Trial.
13 results